Galapagos N.V.(GLPG)Earnings, Financials & Key Ratios
GLPG•NASDAQ
$27.98
5.0× P/E·Price updated Jun 20, 2026
AboutGalapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Show more
- Revenue$1.11B+303.5%
- EBITDA$557M+490.1%
- Net Income$321M+333.1%
- EPS (Diluted)4.85+333.0%
- Gross Margin97.33%+11.4%
- EBITDA Margin50.1%+196.7%
- Operating Margin45.08%+166.0%
- Net Margin28.85%+7.3%
- ROE10.47%+302.1%
GLPG Price & Volume
Galapagos N.V. (GLPG) stock price & volume — 10-year historical chart
Loading chart...
Revenue Volatility Masks Structural Clinical Burn Risk
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Rapid liquidity depletion
Key Thesis Takeaways
- Galapagos N.V.
- faces a precarious transition as it pivots toward early-stage oncology, with its financial health heavily dependent on non-recurring milestone payments rather than sustainable commercial product demand.
- The company's reliance on high-burn R&D, which peaked at $573.7M in 2024Q4, creates significant liquidity pressure as cash reserves have dwindled to $66.8M by 2026Q1.
- Investors should monitor the firm's ability to maintain operations without dilutive financing, given the persistent disconnect between reported accounting profits and negative operating cash flows.
Verdict Logic
the rapid depletion of cash reserves to $66.8M in 2026Q1, combined with deeply negative free cash flow margins, suggests an unsustainable operational trajectory that warrants extreme caution.
GLPG Growth Metrics
Galapagos N.V. (GLPG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years39.6%
5 Years18.4%
3 Years66.44%
TTM262.17%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM388.3%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM379.92%
Return on Capital
10 Years-0.57%
5 Years0.16%
3 Years2.39%
Last Year14.22%
GLPG Recent Earnings
Galapagos N.V. (GLPG) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 6/12 qtrs (55%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.25+119.7%
$1.27
Rev
$9M-20.4%
$11M
Q1 2026
Feb 23, 2026Metric
Actual
Est
EPS
$16.38+1538.0%
$1.00
Rev
$1.2B+1370.9%
$84M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$3.59-1696.4%
$0.20
Rev
$83M+4.0%
$80M
Q3 2025
Jul 23, 2025Metric
Actual
Est
EPS
$1.89-182.3%
$0.67
Rev
$77M-5.1%
$81M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.25vs $1.27+119.7% | $9Mvs $11M-20.4% |
| Q1 2026 | Feb 23, 2026 | $16.38vs $1.00+1538.0% | $1.2Bvs $84M+1370.9% |
| Q4 2025 | Nov 5, 2025 | $3.59vs $0.20-1696.4% | $83Mvs $80M+4.0% |
| Q3 2025 | Jul 23, 2025 | $1.89vs $0.67-182.3% | $77Mvs $81M-5.1% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Galapagos N.V. (GLPG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $27.98 | $1.84B | 5.01 | 303.5% | 28.85% | 10.47% | — | |
| $6.82 | $193.85M | -2.84 | -51.43% | -173.47% | -36.55% | — | |
| $23.72 | $4.06B | 10.36 | 11.87% | 34.3% | 35.65% | — | |
| $72.64 | $8.62B | 28.37 | 37.55% | 23.13% | 126.27% | — | |
| $53.23 | $13.52B | 19.15 | 6.98% | 35.08% | 40.21% | — | |
| $78.34 | $12.95B | -32.92 | 33.87% | -30.87% | -58.57% | — |
Compare GLPG vs Peers
Galapagos N.V. (GLPG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when GLPG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GLPG Frequently Asked Questions
Galapagos N.V. (GLPG) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Galapagos N.V.'s revenue?
Galapagos N.V. (GLPG) reported $1.04B in revenue for fiscal year 2025. This represents a 13321% increase from $7.8M in 2004.
How fast is Galapagos N.V. growing?
Galapagos N.V. (GLPG) grew revenue by 303.5% over the past year. This is strong growth.
Is GLPG profitable?
Yes, Galapagos N.V. (GLPG) is profitable, generating $488.8M in net income for fiscal year 2025 (28.8% net margin).
Dividend & Returns
What is GLPG's return on equity?
Galapagos N.V. (GLPG) has a return on equity (ROE) of 10.5%. This is reasonable for most industries.
What is Galapagos N.V.'s free cash flow?
Galapagos N.V. (GLPG) had negative free cash flow of $304.5M in fiscal year 2025, likely due to heavy capital investments.